5'AMP activated protein kinase expression in human skeletal muscle: effects of strength training and type 2 diabetes.
Strength training enhances insulin sensitivity and represents an alternative to endurance training for patients with type 2 diabetes (T2DM). The 5'AMP-activated protein kinase (AMPK) may mediate adaptations in skeletal muscle in response to exercise training; however, little is known about adaptations within the AMPK system itself. We investigated the effect of strength training and T2DM on the isoform expression and the heterotrimeric composition of the AMPK in human skeletal muscle. Ten patients with T2DM and seven healthy subjects strength trained (T) one leg for 6 weeks, while the other leg remained untrained (UT). Muscle biopsies were obtained before and after the training period. Basal AMPK activity and protein/mRNA expression of both catalytic (alpha1 and alpha2) and regulatory (beta1, beta2, gamma1, gamma2a, gamma2b and gamma3) AMPK isoforms were independent of T2DM, whereas the protein content of alpha1 (+16%), beta2 (+14%) and gamma1 (+29%) was higher and the gamma3 content was lower (-48%) in trained compared with untrained muscle (all P < 0.01). The majority of alpha protein co-immunoprecipitated with beta2 and alpha2/beta2 accounted for the majority of these complexes. gamma3 was only associated with alpha2 and beta2 subunits, and accounted for approximately 20% of all alpha2/beta2 complexes. The remaining alpha2/beta2 and the alpha1/beta2 complexes were associated with gamma1. The trimer composition was unaffected by T2DM, whereas training induced a shift from gamma3- to gamma1-containing trimers. The data question muscular AMPK as a primary cause of T2DM whereas the maintained function in patients with T2DM makes muscular AMPK an obvious therapeutic target. In human skeletal muscle only three of 12 possible AMPK trimer combinations exist, and the expression of the subunit isoforms is susceptible to moderate strength training, which may influence metabolism and improve energy homeostasis in trained muscle.
Wojtaszewski
Jørgen F P
JF
The Institute of Exercise and Sport Sciences, The Copenhagen Muscle Research Centre, University of Copenhagen, 13 Universitetsparken, 2100-Copenhagen, Denmark. jwojtaszewski@aki.ku.dk
Birk
Jesper B
JB
Frøsig
Christian
C
Holten
Mads
M
Pilegaard
Henriette
H
Dela
Flemming
F
D055372:AMP-Activated Protein Kinases; D003924:Diabetes Mellitus, Type 2 / Q000201:enzymology* / Q000235:genetics; D015444:Exercise / Q000502:physiology*; D015971:Gene Expression Regulation, Enzymologic / Q000502:physiology*; D006801:Humans; D007527:Isoenzymes / Q000096:biosynthesis / Q000235:genetics; D008875:Middle Aged; D009097:Multienzyme Complexes / Q000096:biosynthesis* / Q000235:genetics; D018482:Muscle, Skeletal / Q000201:enzymology*; D017346:Protein Serine-Threonine Kinases / Q000096:biosynthesis* / Q000235:genetics; D021122:Protein Subunits / Q000096:biosynthesis* / Q000235:genetics
D007527:Isoenzymes; D009097:Multienzyme Complexes; D021122:Protein Subunits; C526181:PRKAA2 protein, human; C526182:PRKAB1 protein, human; C526183:PRKAB2 protein, human; C526222:PRKAG1 protein, human; C526225:PRKAG3 protein, human; D017346:Protein Serine-Threonine Kinases; D055372:AMP-Activated Protein Kinases; C526180:PRKAA1 protein, human
FEBS Lett. 1999 Oct 29;460(2):343-8
10544261
Anal Biochem. 1987 Apr;162(1):156-9
2440339
Biochem J. 2000 Mar 15;346 Pt 3:659-69
10698692
Science. 2000 May 19;288(5469):1248-51
10818001
Diabetes. 2000 Apr;49(4):527-31
10871188
Biochem Biophys Res Commun. 2000 Jul 14;273(3):1150-5
10891387
Am J Physiol Endocrinol Metab. 2000 Oct;279(4):E806-14
11001762
J Physiol. 2000 Oct 1;528 Pt 1:221-6
11018120
Am J Physiol Endocrinol Metab. 2000 Nov;279(5):E1202-6
11052978
Diabetes. 2001 Jan;50(1):12-7
11147776
Diabetes. 2001 May;50(5):921-7
11334434
Am J Physiol Endocrinol Metab. 2001 Dec;281(6):E1340-6
11701451
Am J Physiol Endocrinol Metab. 2002 Jan;282(1):E18-23
11739078
J Clin Invest. 2002 Feb;109(3):357-62
11827995
Am J Physiol Endocrinol Metab. 2002 Jul;283(1):E178-86
12067859
Diabetes. 2002 Jul;51(7):2074-81
12086935
Am J Physiol. 1992 Dec;263(6 Pt 1):E1134-43
1476187
J Physiol. 1993 Sep;469:615-24
8271219
J Appl Physiol (1985). 1994 Jun;76(6):2386-93
7928862
J Biol Chem. 1994 Nov 25;269(47):29343-6
7961907
Diabetes. 1995 Sep;44(9):1010-20
7657022
J Biol Chem. 1996 Jan 12;271(2):611-4
8557660
J Biol Chem. 1996 Apr 26;271(17):10282-90
8626596
Am J Physiol. 1996 Feb;270(2 Pt 1):E299-304
8779952
FEBS Lett. 1996 Nov 18;397(2-3):347-51
8955377
FEBS Lett. 1997 Jun 16;409(3):452-6
9224708
J Biol Chem. 1998 May 15;273(20):12443-50
9575201
Am J Physiol. 1999 Jul;277(1 Pt 1):E1-10
10409121
J Biol Chem. 1999 Aug 27;274(35):24896-900
10455163
Diabetes. 2002 Oct;51(10):2886-94
12351423
Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):15983-7
12444247
J Clin Invest. 2003 Jan;111(1):91-8
12511592
J Appl Physiol (1985). 2003 Feb;94(2):631-41
12391032
Biochem Soc Trans. 2003 Feb;31(Pt 1):236-41
12546693
Diabetes. 2003 Mar;52(3):657-62
12606505
J Appl Physiol (1985). 2003 Apr;94(4):1373-9
12496137
Diabetes. 2003 May;52(5):1066-72
12716734
Scand J Med Sci Sports. 2003 Jun;13(3):169-74
12753489
Am J Physiol Endocrinol Metab. 2004 Feb;286(2):E239-44
14532170
Am J Physiol Endocrinol Metab. 2004 Feb;286(2):E194-200
14559719
J Biol Chem. 2004 Jan 9;279(2):1070-9
14573616
Am J Physiol Cell Physiol. 2004 Feb;286(2):C283-92
14512293
Diabetes. 2004 Feb;53(2):294-305
14747278
Am J Physiol Endocrinol Metab. 2004 Mar;286(3):E411-7
14613924
J Biol Chem. 2004 Sep 10;279(37):38441-7
15247217
J Clin Endocrinol Metab. 2004 Sep;89(9):4575-80
15356065
J Appl Physiol (1985). 1999 Nov;87(5):1990-5
10562646